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Introduction Multimorbidity and adverse drug reactions (ADR) are 
problems associated with ageing populations.  Exploring underlying 
genetic predispositions might help to risk-stratify patients for early 
intervention. The nuclear factor erythroid 2-like 2 (Nrf2) protein 
regulates antioxidant and de-toxifying effectors in the cell. Nrf2 
expression declines with age, potentially increasing vulnerability to 
multimorbidity and ADR.  We hypothesise that single nucleotide 
polymorphisms (SNPs) at 3 loci in the Nrf2 gene are associated with 
multimorbidity and ADR in older adults.     
Methods  One-hundred and twenty-seven patients were recruited from a 
sub-population of the PRIME study (a multicentre prospective cohort 
study that followed older adults over 8-weeks post-discharge to 
determine ADR status).  Donated genetic material was sequenced to 
determine genotype at 3 loci: rs6721961, rs35652124 and rs6706649 and 
then analysed for association with ADR (Naranjo Algorithm), 
multimorbidity (≥3 conditions defined by the Charlson Index (CI)). 
Results One-hundred and twelve patients (mean age 76.6±7.3 years, 55.4% 
female) were successfully genotyped.  In patients aged 65-79, those 
with the rs35652124 A allele showed increased odds of having ≥3 co-
morbidities (OR 9.03 95%CI 1.16-70.2, p=0.0127). Individuals with the 
CGG haplotype in this age-group showed reduced odds of multimorbidity 
(OR 0.11, 95% CI 0.01-0.86, p=0.001).  No association between Nrf2 
geno/haplotype and ADR was identified. 
Conclusions Polymorphisms in the Nrf2 gene are associated with 
multimorbidity, but not ADR, in older adults.  
 
 
 
 
 
